Skip to Main Content

Paper Details

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nat Commun
1
2023
CD73 antibody, PD-L1, Paclitaxel, adenosine, anti-, anti-PD-L1 durvalumab, carboplatin, mTNBC, metastatic triple-negative breast cancer, oleclumab, paclitaxel, patients, triple-negative breast cancer, women
Author NameAffiliation
Kevin PunieLeuven Cancer Institute, University Hospitals Leuven
Christos SotiriouUniversite Libre de Bruxelles (ULB), Hopital Universitaire de Bruxelles (HUB), Institut Jules Bordet
  • 1 - 2

Datasets

Release 1.2